RL-1620 binds to endothelin B receptors that are important for brain development and by stimulation, these receptors can help to protect the nervous system.
Risk Factors for Alzheimers Disease
Cognitively normal adults exhibiting atrophy of their temporal lobe or damage to blood vessels in the brain are more likely to develop Alzheimer’s disease.
Cognitively normal adults exhibiting atrophy of their temporal lobe or damage to blood vessels in the brain are more likely to develop Alzheimer’s disease.
Dr.Seema Briyal said, "We used the novel approach of stimulating the endothelin B receptors by intravenous injection of IRL-1620 to prevent and repair the damage to the brain caused by Alzheimer’s disease."
Rats with Alzheimer’s disease show an impaired learning and memory capacity as oxidative stress increases. The study showed that IRL-1620 reversed those effects, and intravenous injection with the drug improved memory by 50 to 60 percent and reduced oxidative stress by 45 to 50 percent.
Young Blood to Cure Decline of Aging Brain
A research showed that injections of juvenile mouse blood boosts learning and memory in older rodents, findings that hold the long-sought cure for the decline of ageing brain.
A research showed that injections of juvenile mouse blood boosts learning and memory in older rodents, findings that hold the long-sought cure for the decline of ageing brain.
According to Briyal and her team, this is the first study to demonstrate that intravaneously injecting IRL-1620 can reverse the neurological effects of Alzheimer’s disease by stimulating the endothelin B receptors in rats. This research offers great hope for those suffering from Alzheimer’s disease and their families as currently there is no cure for the debilitating disease.
Advertisement
Understanding Epilepsy, Alzheimer With New Mice Study
Process of working of brain could be better understood with a new study on mice, which could open doors in studying epilepsy, Alzheimer's and other diseases.
Process of working of brain could be better understood with a new study on mice, which could open doors in studying epilepsy, Alzheimer's and other diseases.
World Alzheimer Report 2015: Cases of Dementia To Nearly Triple By 2050
The global cost burden of dementia has risen by more than 35 percent over the last five years to $818 billion (709 billion euros) in 2015.
The global cost burden of dementia has risen by more than 35 percent over the last five years to $818 billion (709 billion euros) in 2015.
